Portal hypertension

Liver Disease in Children, Third Edition

Volumn , Issue , 2007, Pages 138-162

  Shneider, Benjamin L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 43049121227     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511547409.009     Document Type: Chapter

References (238)

1. Goncalves ME, Cardoso SR, Maksoud JG. Prophylactic sclerotherapy in childrenwith esophageal varices: long-termresults of a controlledprospective randomized trial. JPediatr Surg 2000; 35:401–5.
2. Zargar SA, Javid G, Khan BA, et al. Endoscopic ligation comparedwith sclerotherapy for bleeding esophageal varices in children with extrahepatic portal venous obstruction. Hepatology 2002;36:666–72.
3. Shneider B. Approaches to the management of pediatric portal hypertension: Results of an informal survey. In: Groszmann R, Tygat N, Bosch J, eds. Portal hypertension in the 21st century. Boston: Kluwer Academic Publishers, 2004.
4. Ohllson E, Rutherford R, Boitnott J. Changes in portal circulation after biliaryobstruction indogs. Am J Surg 1970;120:16–22.
5. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol 1981;240:G371–5.
6. Okudaira M, Kume H, Ohku M. Experimental portal fibrosis induced by chronic feeding of aflatoxin-B1. In: Sarin SK, ed. Animal models of portal hypertension. New Delhi: Kunj Publishing, 1988:135–41.
7. Sarin SK, Groszmann R, Mosca PG, et al. Propranalol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest 1991;87:1032–6.
8. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984;87:1120–6.
9. Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of e NOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002;283:G1074–81.
10. Biecker E, Neef M, Sagesser H, et al. Nitric oxide synthase 1 is partly compensating for nitric oxide synthase 3 deficiency in nitric oxide synthase 3 knock-out mice and is elevated inmurine and human cirrhosis. Liver Int 2004;24:345–53.
11. Mc Indoe A. Vascular lesions of portal cirrhosis. Arch Pathol 1928;5:23–32.
12. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest 1953;32:1025–33.
13. Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd–Chiari syndrome: a review by an expert panel. J Hepatol 2003;38:364–71.
14. Menon KV, Shah V, Kamath PS. The Budd–Chiari syndrome. N Engl J Med 2004;350:578–85.
15. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd–Chiari syndrome: a common complication of Behcet’s disease. Am J Gastroenterol 1997;92:858–62.
16. Gentil-Kocher S, Bernard O, Brunelle F, et al. Budd–Chiari syndrome in children: report of 22 cases. J Pediatr 1988;113 (1 pt 1):30–8.
17. Safouh M, Shehata AH. Hepatic vein occlusion disease of Egyptian children. J Pediatr 1965;67:415–22.
18. Howard ER, Stringer MD, Mowat AP. Assessment of injection sclerotherapy in the management of 152 children with oesophageal varices. Br J Surg 1988;75:404–8.
19. Alvarez F, Bernard O, Brunelle F, et al. Portal obstruction in children. I. Clinical investigation and hemorrhage risk. J Pediatr 1983;103:696–702.
20. Ahuja V, Marwaha N, Chawla Y, Dilawari JB. Coagulation abnormalities in idiopathic portal venous thrombosis. J Gastroenterol Hepatol 1999;14:1210–11.
21. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587–91.
22. Gauthier-Villars M, Franchi S, Gauthier F, et al. Cholestasis in children with portal vein obstruction. J Pediatr 2005;146: 568–73.
23. Sutton JP, Yarborough DY, Richards JT. Isolated splenic vein occlusion. Review of literature and report of an additional case. Arch Surg 1970;100:623–6.
24. Colman JC, Britton RS, Orrego H, et al. Relation between osmotically induced hepatocyte enlargement and portal hypertension. Am J Physiol 1983;245:G382–7.
25. Orrego H, Blendis LM, Crossley IR, et al. Correlation of intrahepatic pressure with collagen in the Disse space and hepatomegaly in humans and in the rat. Gastroenterology 1981;80: 546–56.
26. Miga D, Sokol RJ, Mackenzie T, et al. Survival after first esophageal variceal hemorrhage in patients with biliary atresia. J Pediatr 2001;139:291–6.
27. D’Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003;38:599–612.
28. Durie PR, Kent G, Phillips MJ, Ackerley CA. Characteristicmultiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockoutmurine model. Am JPathol 2004;164:1481–93.
29. Moser M, Matthiesen S, Kirfel J, et al. A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2005;41:1113–21.
30. McCright B, Lozier J, Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 2002;129:1075–82.
31. Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid frombile and to liver disease. Cell 1993;75:451–62.
32. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28:926–31.
33. Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW, et al. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology 2002;36: 381–5.
34. Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126: 749–55.
35. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:774–8.
36. Martinet JP, Legault L, Cernacek P, et al. Changes in plasma endothelin-1 and Big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patientswith cirrhosis and refractory ascites. J Hepatol 1996;25:700–6.
37. Rockey D. Thecellular pathogenesis of portalhypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997;25:2–5.
38. Kaneda K, Ekataksin W, Sogawa M, et al. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology 1998;27: 735–47.
39. Kojima H, Yamao J, Tsujimoto T, et al. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol 2000;32:43–50.
40. Donovan A, Reynolds T, Mikkelson W. Systemic-portal arteriovenous fistulas: pathologic and hemodynamic observations in two patients. Surgery 1969;66:474–82.
41. Griner P, Elbadani A, Packman C. Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Ann Intern Med 1976;85:578–82.
42. Maksoud JG, Mies S, da Costa Gayotto LC. Hepatoportal sclerosis in childhood. Am J Surg 1986;151:484–8.
43. Sperl W, Stuppner H, Gassner I, et al. Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine- containing herbal tea. Eur J Pediatr 1995;154:112–6.
44. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004;33: 189–95.
45. Okuda K, Kono K, Ohnishi K, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosiswith splenomegaly. Gastroenterology 1984;86:600–10.
46. Bioulac-Sage P, Le Bail B, Bernard PH, Balabaud C. Hepatoportal sclerosis. Semin Liver Dis 1995;15:329–39.
47. Schwerdtfeger E, Abdel-Rahim I, Kardoff R. Ultrasonic invesigation of periportal fibrosis in children with Schistoma mansoni infection: reversibility of morbidity twenty-three years after treatment with praziquantel. Am J Trop Med Hyg 1992; 46:409–15.
48. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52–7.
49. Benoit JN, Barrowman JA, Harper SL, et al. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol 1984;247(5 pt 1):G486–93.
50. Sikuler E, Groszmann RJ. Hemodynamic studies in a parabiotic model of portal hypertension. Experientia 1985;41:1323–4.
51. Silva G, Navasa M, Bosch J, et al. Hemodynamic effects of glucagon in portal hypertension. Hepatology 1990;11:668–73.
52. Kvietys PR, Mc Lendon JM, Granger DN. Postprandial intestinal hyperemia: role of bile salts in the ileum. Am J Physiol 1981;241:G469–77.
53. Genecin P, Polio J, Colombato LA, et al. Bile acids do not mediate the hyperdynamic circulation in portal hypertensive rats. Am J Physiol 1990;259(1 pt 1):G21–5.
54. Thomas SH, Joh T, Benoit JN. Role of bile acids in splanchnic hemodynamic response to chronic portal hypertension. Dig Dis Sci 1991;36:1243–8.
55. Sitzmann JV, Bulkley GB, Mitchell MC, Campbell K. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann Surg 1989;209:322–7.
56. Lee SS, Chilton EL, Pak JM. Adenosine receptor blockade reduces splanchnic hyperemia in cirrhotic rats. Hepatology 1992;15:1107–11.
57. Moller S, Bendtsen F, Schifter S, Henriksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. Scand J Gastroenterol 1996;31:928–33.
58. Fernandez M, Bonkovsky HL. Increased hemeoxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology 1999;29:1672–9.
59. Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827–32.
60. Ros J, Claria J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122:85–93.
61. Pizcueta MP, Pique JM, Bosch J, et al. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992;105: 184–90.
62. Sieber CC, Groszmann RJ. Invitrohyporeactivity tomethoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 1992;262(6 pt 1):G996–1001.
63. Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003;125:1452–61.
64. Lopez-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996;23:1616–21.
65. Genecin P, Polio J, Groszmann RJ. Na restriction blunts expansion of plasma volume and ameliorates hyperdynamic circulation in portal hypertension. Am J Physiol 1990;259(3 pt 1): G498–503.
66. Willett IR, Esler M, Jennings G, Dudley FJ. Sympathetic tone modulates portal venous pressure in alcoholic cirrhosis. Lancet 1986;2:939–43.
67. Mastai R, Rocheleau B, Huet PM. Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension. Hepatology 1989;9:265–8.
68. Pinkerton JA, Holcomb GW Jr, Foster JH. Portal hypertension in childhood. Ann Surg 1972;175:870–86.
69. Spence RA, Johnston GW, Odling-Smee GW, Rodgers HW. Bleeding oesophageal varices with long term follow up. Arch Dis Child 1984;59:336–40.
70. Garcia-Pagan JC, Feu F, Castells A, et al. Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis. Hepatology 1994;19:595–601.
71. Chen L, Groszmann RJ. Blood in the gastric lumen increases splanchnic blood flow and portal pressure in portalhypertensive rats. Gastroenterology 1996;111:1103–10.
72. Lee SS, Hadengue A, Moreau R, et al. Postprandial hemodynamic responses in patients with cirrhosis. Hepatology 1988; 8:647–51.
73. Garcia-Pagan JC, Santos C, Barbera JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996;111:1300–6.
74. Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med 1979;48:627–39.
75. Shah SH, Hayes PC, Allan PL, et al. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portalhypertensiondue tohepatic cirrhosis. Am J Gastroenterol 1996;91:2580–3.
76. Westaby S, Wilkinson SP, Warren R, Williams R. Spleen size and portal hypertension in cirrhosis. Digestion 1978;17:63–8.
77. Yachha SK, Dhiman RK, Gupta R, Ghoshal UC. Endosonographic evaluation of the rectum in children with extrahepatic portal venous obstruction. J Pediatr Gastroenterol Nutr 1996;23:438–41.
78. Weinberg GD, Matalon TA, Brunner MC, et al. Bleeding stomal varices: treatment with a transjugular intrahepatic portosystemic shunt in two pediatric patients. J Vasc Interv Radiol 1995;6:233–6.
79. Fallon MB, Abrams GA, Luo B, et al. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997;113: 606–14.
80. Zhang M, Luo B, Chen SJ, et al. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J Physiol 1999;277(5 pt 1):G944–52.
81. Shah V, Kamath PS. Nitric oxide in liver transplantation: pathobiology and clinical implications. Liver Transpl 2003;9: 1–11.
82. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461–8.
83. Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol 2005;39(4 suppl 2):S138–42.
84. Kinane TB, Westra SJ. Case recordsof the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31–2004. A four-year-old boy with hypoxemia. N Engl J Med 2004;351: 1667–75.
85. Abrams GA, Jaffe CC, Hoffer PB, et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995;109: 1283–8.
86. Santamaria F, Sarnelli P, Celentano L, et al. Noninvasive investigation of hepatopulmonary syndrome in children and adolescents with chronic cholestasis. Pediatr Pulmonol 2002;33: 374–9.
87. Yonemura T, Yoshibayashi M, Uemoto S, et al. Intrapulmonary shunting in biliary atresia before and after living-related liver transplantation. Br J Surg 1999;86:1139–43.
88. Barbe T, Losay J, Grimon G, et al. Pulmonary arteriovenous shunting in children with liver disease. J Pediatr 1995;126: 571–9.
89. Caldwell SH, Jeffers LJ, Narula OS, et al. Ancient remedies revisited: does Allium sativum(garlic) palliate the hepatopulmonary syndrome? J Clin Gastroenterol 1992;15:248–50.
90. Abrams GA, Nanda NC, Dubovsky EV, et al. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998;114:305–10.
91. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995;122:521–9.
92. Krowka MJ, Cortese DA. Hepatopulmonary syndrome. Current concepts in diagnostic and therapeutic considerations. Chest 1994;105:1528–37.
93. Lebrec D, Capron JP, Dhumeaux D, Benhamou JP. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 1979;120:849–56.
94. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest 2003;123:562–76.
95. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10:174–82.
96. Schuijtvlot ET, Bax NM, Houwen RH, Hruda J. Unexpected lethal pulmonary hypertension in a 5-year-old girl successfully treated for biliary atresia. J Pediatr Surg 1995;30:589–90.
97. Soh H, Hasegawa T, Sasaki T, et al. Pulmonary hypertension associatedwith postoperative biliary atresia: report of two cases. J Pediatr Surg 1999;34:1779–81.
98. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25: 502–8.
99. Minder S, Fischler M, Muellhaupt B, et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004;24:703–7.
100. Halank M, Kolditz M, Miehlke S, et al. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan. Wien Med Wochenschr 2005;155:376–80.
101. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004;10:945–50.
102. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005;24:498–500.
103. Losay J, Piot D, Bougaran J, et al. Early liver transplantation is crucial in children with liver disease and pulmonary artery hypertension. J Hepatol 1998;28:337–42.
104. Laving A, Khanna A, Rubin L, et al. Successful liver transplantation in a childwith severe portopulmonaryhypertension treated with epoprostenol. J Pediatr Gastroenterol Nutr 2005;41:466–8.
105. Pirenne J, Verleden G, Nevens F, et al. Combined liver and (heart-)lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. Transplantation 2002;73:140–2.
106. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 1992;102:931–5.
107. Thalheimer U, Triantos CK, Samonakis DN, et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005;54: 556–63.
108. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282–9.
109. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55–64.
110. Ellis D, Avner ED. Renal failure and dialysis therapy in children with hepatic failure in the perioperative period of orthotopic liver transplantation. Clin Nephrol 1986;25:295–303.
111. Wood RP, Ellis D, Starzl TE. The reversal of the hepatorenal syndromein four pediatric patients following successful orthotopic liver transplantation. Ann Surg 1987;205:415–19.
112. Mitra SK, Kumar V, Datta DV, et al. Extrahepatic portal hypertension: a review of 70 cases. J Pediatr Surg 1978;13:51–7.
113. Sarin SK, Agarwal SR. Extrahepatic portal vein obstruction. Semin Liver Dis 2002;22:43–58.
114. Chiu B, Superina R. Extrahepatic portal vein thrombosis is associated with an increased incidence of cholelithiasis. J Pediatr Surg 2004;39:1059–61.
115. de Ville de Goyet J, Gibbs P, Clapuyt P, et al. Original extrahilar approach for hepatic portal revascularization and relief of extrahepatic portal hypertension related to later portal vein thrombosis after pediatric liver transplantation. Long term results. Transplantation 1996;62:71–5.
116. de Ville de Goyet J, Alberti D, Clapuyt P, et al. Direct bypassing of extrahepatic portal venous obstruction in children: a new technique for combined hepatic portal revascularization and treatment of extrahepatic portal hypertension. J Pediatr Surg 1998;33:597–601.
117. Bambini DA, Superina R, Almond PS, et al. Experience with the Rex shunt (mesenterico-left portal bypass) in children with extrahepatic portal hypertension. J Pediatr Surg 2000;35:13–8; discussion 8–9.
118. Utterson EC, Shepherd RW, Sokol RJ, et al. Biliary atresia: clinical profiles, risk factors, and outcomes of 755 patients listed for liver transplantation. J Pediatr 2005;147:180–5.
119. Kasai M, Okamoto A, Ohi R, et al. Changes of portal vein pressure and intrahepatic blood vessels after surgery for biliary atresia. J Pediatr Surg 1981;16:152–9.
120. Miyata M, Satani M, Ueda T, Okamoto E. Long-term results of hepatic portoenterostomy for biliary atresia: special reference to postoperative portal hypertension. Surgery 1974;76:234–7.
121. Ohi R, Mochizuki I, Komatsu K, Kasai M. Portal hypertension after successful hepatic portoenterostomy in biliary atresia. J Pediatr Surg 1986;21:271–4.
122. Lilly JR, Stellin G. Variceal hemorrhage in biliary atresia. J Pediatr Surg 1984;19:476–9.
123. Uflacker R, Pariente DM. Angiographic findings in biliary atresia. Cardiovasc Intervent Radiol 2004;27:486–90.
124. van Heurn LW, Saing H, Tam PK. Portoenterostomy for biliary atresia: long-term survival and prognosis after esophageal variceal bleeding. J Pediatr Surg 2004;39:6–9.
125. Sasaki T, Hasegawa T, Shimizu Y, et al. Portal hypertensive gastropathy after surgery for biliary atresia. Surg Today 2005;35:385–8.
126. Smith S, Wiener ES, Starzl TE, Rowe MI. Stoma-related variceal bleeding: an under-recognized complication of biliary atresia. J Pediatr Surg 1988;23:243–5.
127. Patriquin H, Lafortune M, Weber A, et al. Surgical portosystemic shunts in children: assessment with duplex Doppler US. Work in progress. Radiology 1987;165:25–8.
128. Iwao T, Oho K, Sakai T, et al. Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. J Hepatol 1998;28: 847–55.
129. Annet L, Materne R, Danse E, et al. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003;229:409–14.
130. Taourel P, Blanc P, Dauzat M, et al. Doppler study of mesenteric, hepatic, and portal circulation in alcoholic cirrhosis: relationship between quantitative Doppler measurements and the severity of portal hypertension and hepatic failure. Hepatology 1998;28:932–6.
131. De Giacomo C, Tomasi G, Gatti C, et al. Ultrasonographic prediction of the presence and severity of esophageal varices in children. J Pediatr Gastroenterol Nutr 1989;9:431–5.
132. Patriquin H, Tessier G, Grignon A, Boisvert J. Lesser omental thickness in normal children: baseline for detection of portal hypertension. AJR Am J Roentgenol 1985;145:693–6.
133. Sokal EM, Van Hoorebeeck N, Van Obbergh L, et al. Upper gastro-intestinal tract bleeding in cirrhotic children candidates for liver transplantation. Eur J Pediatr 1992;151:326–8.
134. Zoli M, Merkel C, Magalotti D, et al. Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology 1996;24:1047–52.
135. Bosch J, Bordas JM, Rigau J, et al. Noninvasive measurement of the pressure of esophageal varices using an endoscopic gauge: comparisonwith measurementsby variceal puncture in patients undergoing endoscopic sclerotherapy. Hepatology 1986;6:667–72.
136. Brensing KA, Neubrand M, Textor J, et al. Endoscopic manometry of esophageal varices: evaluation of a balloon technique compared with direct portal pressure measurement. J Hepatol 1998;29:94–102.
137. Ueno K, Hashizume M, Ohta M, et al. Noninvasive variceal pressure measurement may be useful for predicting effect of sclerotherapy for esophageal varices. Dig Dis Sci 1996;41:191–6.
138. El Atti EA, Nevens F, Bogaerts K, et al. Variceal pressure is a strong predictor of variceal haemorrhage in patients with cirrhosis as well as in patients with non-cirrhotic portal hypertension. Gut 1999;45:618–21.
139. Eisen GM, Eliakim R, Zaman A, et al. The accuracy of Pill Cam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: a prospective threecenter pilot study. Endoscopy 2006;38:31–5.
140. Lapalus MG, Dumortier J, Fumex F, et al. Esophageal capsule endoscopy versus Esophagogastroduodenoscopy for evaluating portal hypertension: a prospective comparative study of performance and tolerance. Endoscopy 2006;38:36–41.
141. Bismuth H, Franco D, Alagille D. Portal diversion for portal hypertension in children. The first ninety patients. Ann Surg 1980;192:18–24.
142. Baert AL, Fevery J, Marchal G, et al. Early diagnosis of Budd–Chiari syndrome by computed tomography and ultrasonography: report of five cases. Gastroenterology 1983;84:587–95.
143. Ozsoylu S, Kocak N, Yuce A. Propranolol therapy for portal hypertension in children. J Pediatr 1985;106:317–21.
144. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401–7.
145. Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996;111:701–9.
146. Groszmann RJ. The hepatic venous pressure gradient: has the time arrived for its application in clinical practice? Hepatology 1996;24:739–41.
147. Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056–9.
148. Piscaglia F, Gaiani S, Donati G, et al. Doppler evaluation of the effects of pharmacological treatment of portal hypertension. Ultrasound Med Biol 1999;25:923–32.
149. D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332–54.
150. D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475–505.
151. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001;33:802–7.
152. Banares R, Albillos A, Rincon D, et al. Endoscopic treatmentversus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002;35:609–15.
153. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254–61.
154. Gotoh Y, Iwakiri R, Sakata Y, et al. Evaluation of endoscopic variceal ligation in prophylactic therapy for bleeding of oesophageal varices: a prospective, controlled trial compared with endoscopic injection sclerotherapy. J Gastroenterol Hepatol 1999;14:241–4.
155. Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999;340:988–93.
156. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:65–72.
157. de Kolster CC, Rapa de Higuera M, Carvajal A, et al. [Propranolol in children and adolescents with portal hypertension: its dosage and the clinical, cardiovascular and biochemical effects]. G E N 1992;46:199–207.
158. Shashidhar H, Langhans N, Grand RJ. Propranolol in prevention of portalhypertensivehemorrhage inchildren: a pilot study. J Pediatr Gastroenterol Nutr 1999;29:12–17.
159. Ozsoylu S, Kocak N, Demir H, et al. Propranolol for primary and secondary prophylaxis of variceal bleeding in children with cirrhosis. Turk J Pediatr 2000;42:31–3.
160. Lebrec D, Poynard T, Bernuau J, et al. A randomized controlled studyofpropranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984;4:355–8.
161. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. NEngl JMed 1987;317:856–61.
162. Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990;336:153–6.
163. Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991;114:869–73.
164. Merkel C, Marin R, Enzo E, et al. Randomized trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L’ipertensione portale (GTIP). Lancet 1996;348:1677–81.
165. Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996;25:909–15.
166. Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002;36:1367–73.
167. Lui HF, Stanley AJ, Forrest EH, et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002;123:735–44.
168. Chalasani N, Boyer TD. Primary prophylaxis against variceal bleeding: beta-blockers, endoscopic ligation, or both? Am J Gastroenterol 2005;100:805–7.
169. Elizalde JI, Moitinho E, Garcia-Pagan JC, et al. Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. J Hepatol 1998;29: 789–95.
170. Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, et al. Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clin Gastroenterol Hepatol 2004;2:78–84.
171. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004;39:746–53.
172. Rolando N, Gimson A, Philpott-Howard J, et al. Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. J Hepatol 1993;18:290–4.
173. Terblanche J, Burroughs AK, Hobbs KE. Controversies in the management of bleeding esophageal varices (1). N Engl J Med 1989;320:1393–8.
174. Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of earlymeasurements of portal pressure inacute variceal bleeding. Gastroenterology 1999;117:626–31.
175. Mc Kiernan PJ. Treatment of variceal bleeding. Gastrointest Endosc Clin N Am 2001;11:789–812, viii.
176. Hill ID, Bowie MD. Endoscopic sclerotherapy for control of bleeding varices in children. Am J Gastroenterol 1991;86: 472–6.
177. Mowat AP. Liver disorders in childhood. 2nd ed. London: Buttersworth, 1987.
178. Bosch J, Groszmann RJ, Garcia-Pagan JC, et al. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. Hepatology 1989;10:962–8.
179. Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology 1986;6:112–5.
180. Kravetz D, Bosch J, Teres J, et al. Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. Hepatology 1984;4:442–6.
181. Burroughs AK, McCormick PA, Hughes MD, et al. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology 1990;99: 1388–95.
182. Eroglu Y, Emerick KM, Whitingon PF, Alonso EM. Octreotide therapy for controlof acute gastrointestinal bleeding in children. J Pediatr Gastroenterol Nutr 2004;38:41–7.
183. Heikenen JB, Pohl JF, Werlin SL, Bucuvalas JC. Octreotide in pediatric patients. J Pediatr Gastroenterol Nutr 2002;35: 600–9.
184. Zellos A, Schwarz KB. Efficacy of octreotide in children with chronic gastrointestinal bleeding. J Pediatr Gastroenterol Nutr 2000;30:442–6.
185. Siafakas C, Fox VL, Nurko S. Use of octreotide for the treatment of severe gastrointestinal bleeding in children. J Pediatr Gastroenterol Nutr 1998;26:356–9.
186. Mottet C, Sieber CC, Nauer A, et al. Hemodynamic effects of the somatostatin analog lanreotide in humans: placebocontrolled, cross-over dose-ranging echo-Doppler study. Hepatology 1998;27:920–5.
187. Thapa BR, Mehta S. Endoscopic sclerotherapy of esophageal varices in infants and children. J Pediatr Gastroenterol Nutr 1990;10:430–4.
188. Ho H, Zuckerman MJ, Wassem C. A prospective controlled study of the risk of bacteremia in emergency sclerotherapy of esophageal varices. Gastroenterology 1991;101:1642–8.
189. Van Stiegmann G. Endoscopic ligation of esophageal varices. Am J Surg 1988;156(3 pt 2):9B–12B.
190. Hall RJ, Lilly JR, Stiegmann GV. Endoscopic esophageal varix ligation: technique and preliminary results in children. J Pediatr Surg 1988;23:1222–3.
191. Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992;326:1527–32.
192. Panes J, Teres J, Bosch J, Rodes J. Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices. Results in 151 consecutive episodes. Dig Dis Sci 1988;33: 454–9.
193. Novis BH, Duys P, Barbezat GO, et al. Fibreoptic endoscopy and the use of the Sengstaken tube in acute gastrointestinal haemorrhage in patients with portal hypertension and varices. Gut 1976;17:258–63.
194. Millar AJ, Brown RA, Hill ID, et al. The fundal pile: bleeding gastric varices. J Pediatr Surg 1991;26:707–9.
195. Iwatsuki S, Starzl TE, Todo S, et al. Liver transplantation in the treatment of bleeding esophageal varices. Surgery 1988;104: 697–705.
196. Rasinska G, Wermenski K, Rajszys P. Percutaneous transsplenic embolization of esophageal varices in a 5-year-old child. Acta Radiol 1987;28:299–301.
197. L’Hermine C, Chastanet P, Delemazure O, et al. Percutaneous transhepatic embolization of gastroesophageal varices: results in 400 patients. AJR Am J Roentgenol 1989;152:755–60.
198. Johnson SP, Leyendecker JR, Joseph FB, et al. Transjugular portosystemic shunts in pediatric patients awaiting liver transplantation. Transplantation 1996;62:1178–81.
199. Cao S, Monge H, Semba C, et al. Emergency transjugular intrahepatic portosystemic shunt (TIPS) in an infant: a case report. J Pediatr Surg 1997;32:125–7.
200. Price MR, Sartorelli KH, Karrer FM, et al. Management of esophageal varices in children by endoscopic variceal ligation. J Pediatr Surg 1996;31:1056–9.
201. Maksoud JG, Goncalves ME, Porta G, et al. The endoscopic and surgical management of portal hypertension in children: analysis of 123 cases. J Pediatr Surg 1991;26:178–81.
202. Yachha SK, Sharma BC, Kumar M, Khanduri A. Endoscopic sclerotherapy for esophageal varices in children with extrahepatic portal venous obstruction: a follow-up study. J Pediatr Gastroenterol Nutr 1997;24:49–52.
203. Fox VL, Carr-Locke DL, Connors PJ, Leichtner AM. Endoscopic ligation of esophageal varices in children. J Pediatr Gastroenterol Nutr 1995;20:202–8.
204. Sasaki T, Hasegawa T, Nakajima K, et al. Endoscopic variceal ligation in the management of gastroesophageal varices in postoperative biliary atresia. J Pediatr Surg 1998;33:1628–32.
205. Mc Kiernan PJ, Beath SV, Davison SM. A prospective study of endoscopic esophageal variceal ligation using a multiband ligator. J Pediatr Gastroenterol Nutr 2002;34:207–11.
206. Sarin SK, Kumar A. Sclerosants for variceal sclerotherapy: a critical appraisal. Am J Gastroenterol 1990;85:641–9.
207. Sclerotherapy after first variceal hemorrhage in cirrhosis. Arandomizedmulticenter trial. The Copenhagen Esophageal Varices Sclerotherapy Project. N Engl J Med 1984;311:1594–600.
208. Westaby D, Macdougall BR, Williams R. Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial. Hepatology 1985;5:827–30.
209. Infante-Rivard C, Esnaola S, Villeneuve JP. Role of endoscopic variceal sclerotherapy in the long-termmanagement of variceal bleeding: a meta-analysis. Gastroenterology 1989;96:1087–92.
210. Vane DW, Boles ET Jr, Clatworthy HW Jr. Esophageal sclerotherapy: an effective modality in children. J Pediatr Surg 1985;20:703–7.
211. Hassall E, Berquist WE, Ament ME, et al. Sclerotherapy for extrahepatic portal hypertension in childhood. J Pediatr 1989; 115:69–74.
212. Polson RJ, Westaby D, Gimson AE, et al. Sucralfate for the prevention of early rebleeding following injection sclerotherapy for esophageal varices. Hepatology 1989;10:279–82.
213. Seidman E, Weber AM, Morin CL, et al. Spinal cord paralysis following sclerotherapy for esophageal varices. Hepatology 1984;4:950–4.
214. Helpap B, Bollweg L. Morphological changes in the terminal oesophagus with varices, following sclerosis of the wall. Endoscopy 1981;13:229–33.
215. Gerhartz HH, Sauerbruch T, Weinzierl M, Ruckdeschel G. Nosocomial septicemia in patients undergoing sclerotherapy for variceal hemorrhage. Endoscopy 1984;16:129–30.
216. Carr-Locke DL, Sidky K. Broncho-oesophageal fistula: a late complication of endoscopic variceal sclerotherapy. Gut 1982;23: 1005–7.
217. Tabibian N, Schwartz JT, Smith JL, Graham DY. Cardiac tamponade as a result of endoscopic sclerotherapy: report of a case. Surgery 1987;102:546–7.
218. Greenholz SK, Hall RJ, Sondheimer JM, et al. Manometric and p H consequences of esophageal endosclerosis in children. J Pediatr Surg 1988;23(1 pt 2):38–41.
219. Ohnuma N, Takahashi H, Tanabe M, et al. Endoscopic variceal ligation using a clipping apparatus in children with portal hypertension. Endoscopy 1997;29:86–90.
220. Saeed ZA. The Saeed Six-Shooter: a prospective study of a new endoscopic multiple rubber-band ligator for the treatment of varices. Endoscopy 1996;28:559–64.
221. Laine L, Cook D. Endoscopic ligation comparedwith sclerotherapy for treatment of esophageal variceal bleeding. A metaanalysis. Ann Intern Med 1995;123:280–7.
222. Sarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997;26:826–32.
223. Fonkalsrud EW. Surgical management of portal hypertension in childhood: long-term results. Arch Surg 1980;115:1042–5.
224. Alvarez F, Bernard O, Brunelle F, et al. Portal obstruction in children. II. Results of surgical portosystemic shunts. J Pediatr 1983;103:703–7.
225. Mitra SK, Rao KL, Narasimhan KL, et al. Side-to-side lienorenal shuntwithout splenectomy in noncirrhotic portal hypertension in children. J Pediatr Surg 1993;28:398–401; discussion 402.
226. Prasad AS, Gupta S, Kohli V, et al. Proximal splenorenal shunts for extrahepatic portal venousobstruction in children. Ann Surg 1994;219:193–6.
227. Evans S, Stovroff M, Heiss K, Ricketts R. Selective distal splenorenal shunts for intractable variceal bleeding in pediatric portal hypertension. J Pediatr Surg 1995;30:1115–18.
228. Shun A, Delaney DP, Martin HC, et al. Portosystemic shunting for paediatric portal hypertension. J Pediatr Surg 1997;32:489–93.
229. Dasgupta R, Roberts E, Superina RA, Kim PC. Effectiveness of Rex shunt in the treatment of portal hypertension. J Pediatr Surg 2006;41:108–12; discussion 112.
230. Terblanche J, Burroughs AK, Hobbs KE. Controversies in the management of bleeding esophageal varices (2). N Engl J Med 1989;320:1469–75.
231. Huang YH, Yeh HZ, Chen GH, et al. Endoscopic treatment of bleeding gastric varices by N-butyl-2-cyanoacrylate (Histoacryl) injection: long-term efficacy and safety. Gastrointest Endosc 2000;52:160–7.
232. Greenwald BD, Caldwell SH, Hespenheide EE, et al. N-2-butylcyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysis. Am J Gastroenterol 2003;98:1982–8.
233. Heyman MB, La Berge JM, Somberg KA, et al. Transjugular intrahepatic portosystemic shunts (TIPS) in children. J Pediatr 1997;131:914–19.
234. Hackworth CA, Leef JA, Rosenblum JD, et al. Transjugular intrahepatic portosystemic shunt creation in children: initial clinical experience. Radiology 1998;206:109–14.
235. Heyman MB, La Berge JM. Role of transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension in pediatric patients. J Pediatr Gastroenterol Nutr 1999;29:240–9.
236. Vignali C, Bargellini I, Grosso M, et al. TIPS with expanded polytetrafluoroethylene-covered stent: results of an Italianmulticenter study. AJR Am J Roentgenol 2005;185:472–80.
237. Shneider B, Emre S, Groszmann R, et al. Portal hypertension in children: expertpediatricopiniononthe report of the Baveno IV consensusworkshop on the methodology of diagnosis and therapy in portal hypertension. Pediatr Transplant 2006;10:893–907.
238. Superina R, Shneider B, Emre S, et al. Surgical guidelines for the management of extra-hepatic portal vein obstruction. Pediatr Transplant 2006;10:908–13.